Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies
Stuart C. Gordon(United States Department of Veterans Affairs), Marlyn J. Mayo(Southwestern Medical Center), Won Young Tak(Kyungpook National University Hospital), John R. Lake(University of Minnesota), John M. Vierling(Baylor College of Medicine), Aliya Gulamhusein(Toronto General Hospital), Liana Gheorghe(Carol Davila University of Medicine and Pharmacy), Aparna Goel(Stanford University), Christopher L. Bowlus(University of California, Davis), Charles A. McWherter(University Health Network), Alexandra Steinberg(CymaBay Therapeutics (United States)), B. Freilich(Kansas City Research Institute), Cynthia Levy(University of Miami), Sook‐Hyang Jeong(Seoul National University), Palak Trivedi(University Hospitals Birmingham NHS Foundation Trust), Joseph A. Odin(University of Pittsburgh), Carmen Stanca, Stephen A. Harrison(Pinnacle Clinical Research), Seung Up Kim(Yonsei University), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Jonathan Huang, Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), Lisa Forman(Center for Clinical Research (United States)), Guy Neff, Bruce R. Bacon(Saint Louis University), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Galambos Michael, M Suárez González, Kehu Yang(Nanjing Medical University), Hillel Tobias, Douglas Thorburn(Royal Free London NHS Foundation Trust)
Unknown
January 1, 2021
Cited by 0
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k